NASDAQ: VCNX - Vaccinex, Inc.

Yield per half year: -63.23%
Sector: Healthcare

Share chart Vaccinex, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease.

More details
It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.0316
EV/EBITDA -1.92
IPO date 2018-08-09
ISIN US9186401033
Industry Biotechnology
P/BV -27.98
P/S 121.66
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.000523
Сайт https://www.vaccinex.com
Цена ао 7.55
Число акций ао 0.0004637 млрд
Change price per day: -6.38% (2.82)
Change price per week: -21.43% (3.36)
Change price per month: -51.29% (5.42)
Change price per 3 month: -60.89% (6.75)
Change price per half year: -63.23% (7.18)
Change price per year: +140% (1.1)
Change price per 3 year: +17.33% (2.25)
Change price per 5 year: -54.01% (5.74)
Change price per 10 year: 0% (2.64)
Change price per year to date: +125.64% (1.17)
All parameters

Underestimation

Title Value Grade
P/S 8.37 1
P/BV -2.06 0
P/E 0 0
EV/EBITDA -0.153 0
Total: 3.88

Efficiency

Title Value Grade
ROA, % -557.73 0
ROE, % 876.29 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0108 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 8.99 2
Yield Ebitda, % -27.96 0
Yield EPS, % 1654.1 10
Total: 2.4
More

Institutions Volume Share, %
AIGH Capital Management LLC 58362 4.74
Worth Venture Partners, LLC 46720 3.79
Vanguard Group Inc 3444 0.28
Renaissance Technologies, LLC 2293 0.19
Two Sigma Investments, LP 1154 0.09
Geode Capital Management, LLC 1150 0.09
XTX Topco Ltd 838 0.07
Tower Research Capital LLC (TRC) 475 0.04
Group One Trading, L.P. 65 0.01
UBS Group AG 24 0



Head Job title Payment Year of birth
Dr. Maurice Zauderer Ph.D. Co-Founder, CEO, President & Director 411.7k 1946 (78 years)
Dr. Elizabeth E. Evans Ph.D. COO and Senior VP of Discovery & Translational Medicine 291.57k 1973 (51 year)
Dr. Ernest S. Smith Ph.D. Senior VP of Research & Chief Scientific Officer 297.25k 1972 (52 years)
Dr. John E. Leonard Ph.D. Senior Vice President of Development N/A 1947 (77 years)
Ms. Jill Sanchez CPA Chief Financial Officer N/A 1972 (52 years)

Address: United States, Rochester. NY, 1895 Mount Hope Avenue - open in Google maps, open in Yandex maps
Website: https://www.vaccinex.com